Many epidemiological studies, particularly those using population-based ascertainment, do not include a substantial proportion of subjects with a cancer family history, and are therefore not enriched for underlying genetic susceptibility ([@bib24]). This can have an impact on both the precision and ability to identify associations if the risk gradient depends on underlying genetic susceptibility (i.e., gene--environment interactions). Improving precision can be readily accomplished through sampling more individuals. However, increasing the sample size without ensuring adequate individuals at greater disease susceptibility are included will limit the ability to detect gene--environment interactions. Thus, the role of a given environmental factor may be under-recognised if gene--environment interactions exist. Using a family-based cohort enriched with individuals across the risk spectrum, we illustrate the importance of having sufficient numbers of individuals across the risk spectrum to properly test the role of environmental factors on cancer risk. We illustrate this concept by estimating the association between polycyclic aromatic hydrocarbons (PAHs) and breast cancer risk as a function of a woman\'s underlying genetic risk inferred from her cancer family history.

Polycyclic aromatic hydrocarbons, a group of compounds with two or more fused benzene rings, are environmental contaminants that play an important carcinogenic role due to widespread population exposure ([@bib18]; [@bib9]). Polycyclic aromatic hydrocarbons can be bio-transformed into reactive intermediates that form covalent PAH-DNA adducts that have mutagenic properties to initiate and/or promote tumorigenesis ([@bib18]). Polycyclic aromatic hydrocarbons are lipophilic, are stored in the fat tissue of the breast and have shown endocrine-disrupting and obesogenic capabilities to cause mammary cancer in rodents ([@bib16]). The potential carcinogenic mechanisms of metabolised PAHs may be partially due to their structural similarities with oestrogenic compounds that affect hormone signalling pathways or increase the bioaccumulation capacity in adipose tissue and increase breast cancer risk ([@bib13]; [@bib30]). Therefore, the International Agency for Research on Cancer has classified selected PAHs, such as benzo\[*a*\]pyrene, as human carcinogens ([@bib9]); the US Environmental Protection Agency (EPA) also lists PAHs as possible carcinogens ([@bib17]).

Several large studies have examined the role of PAHs on breast cancer risk. The Long Island Breast Cancer Study Project (LIBCSP), a population-based case--control study, found a statistically significant increased risk for women with detectable levels of PAH-DNA adducts in blood ([@bib6], [@bib5]), and estimated a 50% greater risk of breast cancer for women in the highest *vs* lowest quintile of PAH-DNA adducts. Breast cancer was increased by 40% for women reporting ever burning synthetic logs (associated with bulky PAH-DNA adducts) in their homes ([@bib27]), and 44% for women exposed to the highest level (*vs* below the median) of vehicular traffic ([@bib15]). Polycyclic aromatic hydrocarbon exposures from other sources, including tobacco smoking ([@bib8]), dietary intake ([@bib25]), grilled and smoked meats([@bib4]; [@bib3]), also contribute to increased breast cancer risk. However, two cohort studies have not observed any associations with PAHs and breast cancer risk that may be due to use of the postlabelling assay that is not specific for PAH adducts or measuring non-carcinogenic PAH markers in urine where urinary measures only reflect short-term exposure ([@bib12]; [@bib20]). A growing number of studies found that exposure to PAHs may further enhance breast cancer risk for women carrying higher susceptibility genetic variants involved in carcinogen metabolism, DNA repair and cell cycle control pathways ([@bib23]; [@bib7]; [@bib14]). These stronger associations in subgroups defined by genetic variants suggests that women with higher breast cancer risk based on family history would also have higher risk but detecting interactions between environmental carcinogens and underlying risk requires a sufficient number of women at higher risk for cancer. We hypothesised that the women at greater risk of breast cancer from PAH exposure are the women who have higher underlying absolute risk of breast cancer predicted from their cancer family history.

Materials and methods
=====================

Study design
------------

We conducted a prospective study within the women unaffected with breast cancer at enrolment in the New York site of the Breast Cancer Family Registry (BCFR), a registry of individuals within families with breast and/or ovarian cancer (for details, see [@bib10]; [@bib19]). At recruitment, each eligible subject completed a questionnaire that included information on demographics, lifestyle and environmental factors, past surgeries and family history of cancer ([@bib10]). We actively followed participants for subsequent information on cancer incidence and vital status and attempted to verify cancers through pathology reviews and reports and medical records. In the current nested case--control study, we analysed data for 80 prospectively ascertained breast cancer cases and 156 age- and ethnicity-matched controls. All cohort participants provided written informed consent, and the study was approved by the relevant local ethics committees.

PAH-albumin adducts
-------------------

We measured plasma PAH-albumin adducts by competitive enzyme linked immunosorbent assay using monoclonal antibody 8E11 that recognises benzo(a)pyrene diolepoxide tetrols and related PAH metabolites. A pooled quality control sample was run within each batch ([@bib21]), and the value was expressed as fmol of PAH per mg albumin.

Absolute risk of breast cancer
------------------------------

We calculated 10-year risk of breast cancer using available family pedigree and vital status data from all family members on cancer diagnoses and age at diagnoses and information on *BRCA1* and *BRCA2* mutations using the risk model BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) ([@bib2], [@bib1]; [@bib11]). We used this probability as a continuous risk score in the regression analyses.

Statistical analysis
--------------------

After descriptive analyses, we used conditional logistic regression based on the matched sets (1 : 2 age and race/ethnicity matched) to estimate breast cancer risk for women with detectable PAH-albumin adducts compared with women with non-detectable adducts (referent). We further categorised detectable adducts based on the median for matched control women with detectable adducts to examine high *vs* low levels of detectable adducts. We considered the potential confounding effects of age at blood draw and body mass index. We further stratified by menopausal status, smoking status, BOADICEA 10-year risk score (⩾3.4 *vs* \<3.4%) and examined interactions across the continuous BOADICEA score by centring PAH at the mean and including an indicator variable for non-detectable levels. We selected 3.4 as a categorical cutoff for absolute 10-year risk because a commonly used clinical cutoff to indicate high risk for 5-year risk is 1.67%. We also compared interactions using a continuous level of PAH-albumin adducts for those with detectable levels and a continuous 10-year BOADICEA score ([Figure 1](#fig1){ref-type="fig"}). We formally tested for statistical significance of interactions through a cross-product term for multiplicative interactions and used the relative excess risk due to interaction (RERI) for additive interactions.

Results
=======

[Table 1](#tbl1){ref-type="table"} summarises the overall association with categorised PAH. The highest category of PAHs was associated with breast cancer risk (OR=2.89, 95% CI: 1.25--6.69). The associations were higher for women with 10-year BOADICEA score ⩾3.4 (OR=4.09, 95% CI: 1.38--12.13) compared with women with a 10-year BOADICEA score \<3.4. The RERI was positive but not statistically significant (RERI=1.75, 95% CI=−1.90, 5.40). [Figure 1](#fig1){ref-type="fig"} shows the association between PAHs and BOADICEA with BOADICEA considered on a continuous scale and PAH levels on a continuous scale for the mean level, the 75th and the 90th percentiles (test for multiplicative interaction *P*=0.09). The higher the absolute risk of breast cancer, the stronger the association with PAHs. There was no interaction with BOADICEA scores for women with non-detectable levels of PAHs.

Discussion
==========

Women with higher PAH albumin adducts had 2--3 times greater breast cancer risk in our cohort. The associations were even stronger for women with higher absolute risk of breast cancer (OR=4.09, 95% CI=1.28--12.13). Our results provide further evidence that PAHs are breast carcinogens and support the stronger associations seen in other studies once subgroups were divided based on risk. For example, in the LIBCSP, traffic-related PAH exposures were positively associated with increased breast cancer risk by interactions with specific polymorphisms in DNA repair genes of *ERCC2*, *XRCC1* and *OGG1* (ORs from 2.32 to 2.96) ([@bib14]). Associations (∼2-fold and higher) were observed for women with greater inherited genetic susceptibility to the effects of PAH due to variants in carcinogen metabolism, DNA repair, response to oxidative stress and cellular apoptosis genes, as well as the tumour suppressor gene *p53* ([@bib23]; [@bib7]). In addition, constitutional DNA methylation in several breast cancer susceptibility genes (*BRCA1*, *PALB2* and *MLH1*) has been associated with increased risk of early-onset breast cancers with genetic mutations (both germline and somatic mutations) ([@bib28]; [@bib22]). Changes in DNA methylation in *RARβ* and *APC* suggest a stronger aetiologic effect of PAH exposure on breast cancer risk for higher susceptibility women ([@bib26]). These results are biologically plausible because genetic mutation can disrupt DNA methylation patterns, and hence, impact gene expression and function. Meanwhile, epigenetic changes precede downstream genetic mutation in tumorigenesis that can disable DNA repair functions ([@bib29]).

These findings also illustrate the benefit of using high-risk cohorts to examine gene--environment interactions as we covered the full range of underlying breast cancer risk unlike many cohorts that predominantly have only a small proportion of women at high risk. Thus, family-based cohorts can be useful not only for gene discovery but as a very effective way to examine environmental exposures. If replicated in larger cohorts, these results support the hypothesis that PAH may be a strong breast carcinogen for women with greater underlying breast cancer susceptibility.
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![**Increase in breast cancer risk from PAH exposure by absolute risk of breast cancer as estimated by the BOADICEA, New York site of the BCFR.** Results from a multivariable conditional logistic regression of breast cancer risk with the following covariates: centred PAH-albumin adducts, indicator variable for women with non-detectable levels, continuous BOADICEA score, interactions between BOADICEA and centred PAH-albumin adducts and indicator variable for women with non-detectable values, and further adjusted for age at blood draw, body mass index and smoking status. *P*-value for multiplicative interaction=0.09.](bjc201781f1){#fig1}

###### Plasma PAH-albumin adducts and breast cancer risk categorised by menopausal status and absolute risk score, New York site of the BCFR

                                                                         **Cases**   **Controls**                                                            
  --------------------------------------------------------------------- ----------- -------------- ---- ------ ----------- ------ ------- ----------- ------ -------
  **All women**                                                                                                                                              
  Non-detectable                                                            27           36.0       72   49.3   Reference                  Reference             
  Detectable                                                                48           64.0       74   50.7     1.90      1.00   3.63      2.04      1.06   3.93
   \<Median[c](#t1-fn3){ref-type="fn"}                                      20           26.7       37   25.3     1.49      0.71   3.15      1.59      0.75   3.39
   ⩾Median                                                                  28           37.3       37   25.3     2.66      1.17   6.05      2.89      1.25   6.69
  **Premenopausal women only**                                                                                                                               
  Non-detectable                                                            18           36.0       52   50.0   Reference                  Reference             
  Detectable                                                                32           64.0       52   50.0     2.19      0.99   4.83      2.30      1.00   5.27
   \<Median[c](#t1-fn3){ref-type="fn"}                                      15           30.0       27   26.0     1.81      0.73   4.49      1.93      0.73   5.06
   ⩾Median                                                                  17           34.0       25   24.0     2.91      1.03   8.21      2.87      1.01   8.17
  **Interaction with BOADICEA Risk Score**[d](#t1-fn4){ref-type="fn"}                                                                                        
  Non-detect or Detect \<median, \<3.4%                                     12           16.0       38   27.0   Reference                  Reference             
  Detect⩾Median, \<3.4%                                                      7           9.3        15   10.6     1.75      0.54   5.68      1.81      0.55   5.94
  Non-detect or detect \<median, ⩾3.4%                                      35           46.7       68   48.2     1.65      0.72   3.77      1.54      0.66   4.04
  Detect⩾Median, ⩾3.4%                                                      21           28.0       20   14.2     4.01      1.39   11.58     4.09      1.38   12.13

Conditional logistic regression, unadjusted.

Conditional logistic regression, adjusted for age at blood draw, body mass index and smoking status.

Median=73.0 fmol mg^−1^ among controls.

Additive interaction tested using RERI (1.75, 95% CI=−1.90, 5.40).
